Retrospective Clinical Study on Integrated Chinese and Western Medicine in Treatment of Limited-Stage Small Cell Lung Cancer.
10.1007/s11655-022-3682-9
- Author:
Run-Zhi QI
1
;
Shu-Lin HE
2
;
Yue LI
2
;
Yu-Wei ZHAO
2
;
Liang GENG
3
;
Jie HE
2
;
Meng-Qi CHENG
1
;
Jia-Qi HU
2
;
Cong-Huang LI
4
;
Bao-Jin HUA
1
Author Information
1. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing, 100053, China.
2. Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
3. Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou, 100053, China.
4. Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Beijing, 100053, China. liconghuang@163.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
combination of Chinese and Western medicine;
limited-stage small cell lung cancer;
overall survival;
progression-free survival
- MeSH:
Humans;
Small Cell Lung Carcinoma/drug therapy*;
Lung Neoplasms/drug therapy*;
Retrospective Studies;
Prognosis;
Combined Modality Therapy
- From:
Chinese journal of integrative medicine
2023;29(8):675-682
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the efficacy of integrated Chinese and Western medicine extending the progression-free survival (PFS) and overall survival (OS) of limited-stage small cell lung cancer (LS-SCLC) patients after the first-line chemoradiotherapy.
METHODS:The data of 67 LS-SCLC patients who received combined treatment of CM and Western medicine (WM) between January 2013 and May 2020 at the outpatient clinic of Guang'anmen Hospital were retrospectively analyzed. Thirty-six LS-SCLC patients who received only WM treatment was used as the WM control group. The medical data of the two groups were statistically analyzed. Survival analysis was performed using the product-limit method (Kaplan-Meier analysis). The median OS and PFS were calculated, and survival curves were compared by the Log rank test. The cumulative survival rates at 1, 2, and 5 years were estimated by the life table analysis. Stratified survival analysis was performed between patients with different CM administration time.
RESULTS:The median PFS in the CM and WM combination treatment group and the WM group were 19 months (95% CI: 12.357-25.643) vs. 9 months (95% CI: 5.957-12.043), HR=0.43 (95% CI: 0.27-0.69, P<0.001), respectively. The median OS in the CM and WM combination group and the WM group were 34 months (95% CI could not be calculated) vs. 18.63 months (95% CI: 16.425-20.835), HR=0.40 (95% CI: 0.24-0.66, P<0.001), respectively. Similar results were obtained in the further stratified analysis of whether the duration of CM administration exceeded 18 and 24 months (P<0.001).
CONCLUSION:The combination treatment of CM and WM with continuing oral administration of CM treatment after the first-line chemoradiotherapy for LS-SCLC patients produced better prognosis, lower risks of progression, and longer survival than the WM treatment alone. (Registration No. ChiCTR2200056616).
